News | February 02, 2026
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
Subscribe To Our Newsletter & Stay Updated
